This time, Carl Icahn may have chosen a biopharma adversary as stubborn as himself. And that's saying something. Forest Laboratories ($FRX) CEO Howard Solomon shows no sign of backing down in his defense of the company's current regime. And he's perfectly willing to fight eye-to-eye with the activist investor. No shying away from a public argument here. Report